Introduction:

Peptides bound to cell surface MHC molecules allow the immune system to recognize intracellular pathogens and tumor-derived peptides. Each MHC allele has a distinct peptide binding motif which favours certain amino acids at particular points in a sequence. Complete Omics scientists developed and have been keeping on improving a set of methods that could capture essentially all MHC molecules and harvest the peptides presented by those MHC molecules. Through our unique neoantigen detection and quantification platform, we could help you validate neoantigens that are actually presented on the cell surface thus serving as your potential druggable targets before you investing hundreds of thousands of dollars into therapeutic method development, and provide you accurate quantification values for your neoantigen targets. Prediction methods only can predict the binding affinity, and higher affinity does not mean a valid presentation. Our Valid-NEO pipeline is completely PREDICTION-FREE, and we DIRECTLY SEE the data and let the data talk. WE DO NOT GUESS (PREDICT).

There are several milestone papers published by our team demonstrating early versions of our technique (such as MANA-SRM). Our current Valid-NEO pipeline represents a giant leap forward. Please click on the papers below for additional technical details:

Direct Detection and Quantification of Neoantigens. Cancer Immunol Res . 2019 Nov;7(11):1748-1754.

Bispecific antibodies targeting mutant RAS neoantigens. Sci Immunol . 2021 Mar 1;6(57):eabd5515.

Targeting a neoantigen derived from a common TP53 mutation. Science . 2021 Mar 5;371(6533):eabc8697.

Data analysis, including data validation, visualization and quantification, are performed with commercial softwares and Complete Omics’ unique R packages and scripts. Report will be sent to you in Excel format as well as a summary in PDF format. We will also provide you any details you need for your papers’ MATERIALS AND METHODS section. We will make sure you understand your result and help you with your paper writing with free follow-up services.

Sample types we accept:

1, Tissue culture cell pellets

2, Tumor tissue chunk

3, Clinical Biopsy Samples (minimal 5 mg tissue)

4, Biofluids, such as plasma*, serum*, saliva, tear, etc.

*We provide High Abundance Protein Depletion Service to significantly (100-500 folds) increase the depth of your biofluid proteomics analysis by removing top abundant proteins from your samples. Read more for details​.

5, FFPE blocks

6, Customized sample types (please contact us to discuss)

Complete360® Enables Deep Biomarker Profiling in Groundbreaking iPSC CAR‑NK Cell Therapy Study Published in Cell

June 25, 2025 | BALTIMORE – We are thrilled to share that a major milestone in cell therapy has just been published in Cell, showcasing the world’s first-in-human clinical study of…

Read more

Complete Omics Makes Landmark Debut at ASMS 2025

June 5, 2025 | BALTIMORE -Complete Omics Inc. is proud to announce a successful debut at the American Society for Mass Spectrometry (ASMS) 2025 Annual Meeting, held in Baltimore, Maryland.

Read more

Milestone! | Complete Omics Inc. Secures California Clinical Laboratory License, Expanding Access to Cutting-Edge Clinical Proteomics Testing

Feb 20, 2025 | BALTIMORE – Complete Omics Inc., a leader in clinical proteomics and multi-omics molecular diagnostics, proudly announces its recent achievement of the California Clinical Laboratory License. This…

Read more

Some of our impacts